Candriam SCA’s C4 Therapeutics CCCC Stock Holding History

Candriam SCA’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.38M	Buy	+1,796,937	New	+$6.15M	0.04%	307

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Candriam SCA's CCCC Position: Q2 2026 in Review

Candriam SCA opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 1,796,937 shares worth $8.38M. The stake represents 0.04% of the portfolio and ranks #307 among its holdings.

148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Candriam SCA held 1,796,937 shares of C4 Therapeutics worth $8.38M as of Q2 2026.
C4 Therapeutics was a new Candriam SCA position in Q2 2026.
C4 Therapeutics made up 0.04% of Candriam SCA's portfolio in Q2 2026, its #307 holding.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.